Remember meForgot password?
    Log in with Twitter
| Press Release

Free Post Earnings Research Report: Zimmer Biomet’s Quarterly Sales Grew 3%; Topped Expectations

Stock Monitor: Natus Medical Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 09, 2018 / has just released a free earnings report on Zimmer Biomet Holdings, Inc. (NYSE: ZBH). If you want access to this report all you need to do is sign up now by clicking the following link Zimmer Biomet reported its fourth quarter and fiscal 2017 operating and financial results on January 30, 2018. The orthopedic device maker's earnings results were in-line with market estimates. Register today and get access to over 1,000 Free Research Reports by joining our site below: is currently working on the research report for Natus Medical Incorporated (NASDAQ: BABY), which also belongs to the Healthcare sector as the Company Zimmer Biomet Holdings. Do not miss out and become a member today for free to access this upcoming report at: is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zimmer Biomet Holdings most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

Earnings Highlights and Summary

Zimmer Biomet reported fourth quarter 2017 net sales of $2.07 billion, reflecting an increase of 3.0% over Q4 2016 net sales of $2.01 billion. The Company's reported numbers beat analysts' estimates of $2.03 billion.

Zimmer Biomet's full-year (FY) 2017 net sales were $7.82 billion, reflecting an increase of 1.8% over FY16 sales of $7.68 billion. The Company's FY17 revenues increased by 0.5% y-o-y on a constant currency basis, excluding approximately 130 basis points of contribution from the LDR Holding Corp.'s acquisition.

For Q4 2017, Zimmer Biomet's research and development (R&D) expense was 4.6% of revenue at $95.0 million compared to $95.7 million in Q4 2016. During Q4 2017, Zimmer Biomet recorded pretax charges of $668 million in special items, 150 million of which were cash outflows for quality remediation, business integration and other items, non-cash charges related to intangible amortization, certain legal matters, and the goodwill impairment write off related to the Company's spine business unit.

Zimmer Biomet reported net income of $1.26 billion, or $6.16 per diluted share, including a one-time tax benefit of approximately $6.40 per share, resulting from the recently enacted US tax reform legislation. The Company reported net income of $69.6 million, or $0.34 per diluted share, for Q4 2016. Zimmer Biomet's adjusted diluted earnings per share were $2.10 for Q4 2017, reflecting a 1.9% drop on a y-o-y basis.

For FY17, Zimmer Biomet reported net income of $1.84 billion, or $9.03 per diluted share, compared to $305.9 million, or $1.51 per diluted share, for FY16. The Company's adjusted diluted earnings per share were $8.03 for FY17, represent growth of 0.9% compared to the year ago same period.

Zimmer Biomet's Segment Results

During Q4 2017, the Knees segment's net sales grew 1.4% to $731 million on a y-o-y basis, primarily attributed to the stronger US market and increased demand for the Company's Persona Partial knee system.

For Q4 2017, the Hips division's sales advanced 3.5% to $499 million, driven by strong performance in the Asia/Pacific region where the Company had double digit sales growth. Zimmer Biomet's quarterly sales of its Taperloc G7 and Arcos systems improved, however, supply constraints continued to limit the Company's ability to meet the demand of these high growth brands.

During Q4 2017, the Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma (SET) sales grew 5.9% on a y-o-y basis with numerous products across this category contributing to growth. The Company's surgical portfolio recorded solid sales, while within upper extremities, the Company reported strong demand for the comprehensive shoulder.

Cash Matters

During Q4 2017, Zimmer Biomet's operating cash flow was $402.9 million. In the reported quarter, the Company paid $48.6 million in dividends and repaid $300.0 million of debt. For FY 2017, Zimmer Biomet paid $193.6 million in dividends and repaid approximately $1.250 billion of debt.


For the first quarter of 2018, Zimmer Biomet is forecasting revenue in the range of $1.955 billion to $1.995 billion, representing a change of negative 1.0% to positive 1.0% compared to the prior year's same period, and negative 4.0% to negative 2.0% on a constant currency basis compared to the prior year's corresponding period. The Company is estimating earnings for the upcoming quarter to be in the band of $0.73 to $0.88 per share, and in a range of $1.84 to $1.91 per diluted share on an adjusted basis.

Stock Performance Snapshot

February 08, 2018 - At Thursday's closing bell, Zimmer Biomet's stock dropped 4.35%, ending the trading session at $115.53.

Volume traded for the day: 1.66 million shares, which was above the 3-month average volume of 1.45 million shares.

Stock performance in the last three-month – up 6.26%; and previous six-month period – up 2.37%

After yesterday's close, Zimmer Biomet's market cap was at $23.84 billion.

Price to Earnings (P/E) ratio was at 12.80.

The stock has a dividend yield of 0.83%.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Latest News
Top News